The Big Catch-Up has achieved much of what it set out to do. Its legacy could last generations

The Big Catch-Up has delivered over 100 million childhood vaccinations and is on track to reach close to its target of 21 million children, with 36 countries participating and 32 planning to embed catch-up immunisation in national strategies. Since 2019, the number of zero-dose children in lower-income countries rose from 9.3 million to 12.3 million during the pandemic, but catch-up efforts have already reached 18 million children by end-2025. The article is broadly positive for global public health outcomes, though direct market impact is limited.

Analysis

The key market implication is not a direct equity beta story but a multi-year shift in how frontier and emerging-market health systems are financed and executed. A successful catch-up campaign tends to pull forward procurement of pediatric vaccines, cold-chain equipment, last-mile logistics, and digital registry tools, then converts those into recurring spend once ministries embed catch-up into routine protocols. That makes the durable beneficiaries the “picks and shovels” layer—global health logistics, vaccine suppliers with public-sector exposure, and local distributors with existing Ministry of Health relationships—rather than any single headline beneficiary.

The second-order effect is improved system throughput: when zero-dose populations are reached, governments usually discover adjacent unmet demand for antenatal care, nutrition, basic diagnostics, and chronic disease screening. That can lift utilization at low-margin primary-care providers and create incremental funding flows from multilaterals, but it also raises expectations for follow-through, which is where execution risk sits. If fiscal pressures widen or donor budgets reallocate toward higher-priority geopolitical areas, the catch-up momentum could fade after the first implementation wave, especially where the easy-to-reach cohorts were already harvested.

The contrarian point is that the market may be overestimating how linear the benefit curve is. The biggest gains have likely already come from the most addressable cohorts; the remaining children are the most expensive to reach and are disproportionately exposed to conflict, urban hesitation, or weak administrative capacity. That means the next leg is slower and more politically fragile, so any optimism around sustained vaccine-volume growth should be tempered by the risk that coverage plateaus even as headline programs continue, leaving vendors with lumpy order patterns rather than a smooth step-up in demand.

Key Decisions for Investors

• Long DHR / short broad EM healthcare basket over 6-12 months: DHR has recurring exposure to diagnostics, cold-chain adjacent workflows, and public-health infrastructure, while the short leg captures the risk that donor-driven immunization spend disappoints outside the most capable implementers. Target 1.5-2.0x upside vs limited downside if execution broadens.
• Build a basket long in vaccine/logistics enablers: BDX, MTD, and selected private-market proxies for cold-chain/traceability infrastructure; size for 12-24 months. The thesis is less about one procurement cycle and more about ministries embedding catch-up into standard operating procedures, which supports recurring demand.
• Long USD EM sovereign/short local FX exposure in countries with credible public-health execution but weak fiscal buffers. Catch-up success can improve aid optics and disbursement cadence, but it also creates near-term budget pressure; if donor funding slows, FX stress can re-emerge within 3-9 months.
• Avoid chasing pure-play vaccine manufacturers on this headline unless backlog visibility improves. The market may already be discounting a multi-year volume re-acceleration, while the real economic gain accrues to service, distribution, and data-infrastructure layers with more elastic margins.
• Optionality trade: buy 6-12 month calls on a diversified global health/logistics name versus financing with out-of-the-money calls on an over-owned EM consumer proxy. This expresses upside from sustained immunization normalization while limiting downside if the program stalls after the current implementation wave.